Abstract
Ten patients with AIDS and cytomegalovirus (CMV) gastrointestinal infection were included in an open-label study to evaluate the safety, efficacy, and pharmacokinetics of 90 mg of intravenous foscarnet/kg of body weight twice daily accompanied by (pre)hydration of 500 to 750 ml. Efficacy was documented endoscopically, while safety was evaluated clinically by patient reports and physical and laboratory observation. The pharmacokinetics of foscarnet was evaluated after the first dose and following approximately 20 days of therapy. Nine patients (90%) responded histopathologically, nine (90%) responded endoscopically, and nine (90%) responded symptomatically to foscarnet therapy. Adverse events resulted in discontinuance of medication in the case of one patient. The mean maximal concentration was 621 microM following the first dose and 687 microM at steady state (P = 0.11). The apparent elimination rate constant and elimination half-life were not different between dose 1 and steady state. There were no significant changes in foscarnet excretion or renal clearance between dose 1 and steady state. The steady-state volume of distribution was 23.4 liters following the first dose and 19.0 liters at steady state (P < 0.002). Twice-daily foscarnet appeared to be safe and efficacious in the treatment of CMV gastrointestinal disease in this study, resulting in endoscopic or histologic improvement in 9 of the 10 (90%) patients. Minor changes in clearance and volume of distribution noted at steady state compared to single-dose administration are readily explained by study design, known information about foscarnet pharmacokinetics, and changes in body weight and creatinine clearance in the patients.
Full Text
The Full Text of this article is available as a PDF (159.1 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Akesson-Johansson A., Lernestedt J. O., Ringdén O., Lönnqvist B., Wahren B. Sensitivity of cytomegalovirus to intravenous foscarnet treatment. Bone Marrow Transplant. 1986 Dec;1(2):215–220. [PubMed] [Google Scholar]
- Aweeka F., Gambertoglio J., Mills J., Jacobson M. A. Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. Antimicrob Agents Chemother. 1989 May;33(5):742–745. doi: 10.1128/aac.33.5.742. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Blanshard C., Benhamou Y., Dohin E., Lernestedt J. O., Gazzard B. G., Katlama C. Treatment of AIDS-associated gastrointestinal cytomegalovirus infection with foscarnet and ganciclovir: a randomized comparison. J Infect Dis. 1995 Sep;172(3):622–628. doi: 10.1093/infdis/172.3.622. [DOI] [PubMed] [Google Scholar]
- Deray G., Martinez F., Katlama C., Levaltier B., Beaufils H., Danis M., Rozenheim M., Baumelou A., Dohin E., Gentilini M. Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am J Nephrol. 1989;9(4):316–321. doi: 10.1159/000167987. [DOI] [PubMed] [Google Scholar]
- Dieterich D. T., Poles M. A., Dicker M., Tepper R., Lew E. Foscarnet treatment of cytomegalovirus gastrointestinal infections in acquired immunodeficiency syndrome patients who have failed ganciclovir induction. Am J Gastroenterol. 1993 Apr;88(4):542–548. [PubMed] [Google Scholar]
- Dieterich D. T., Rahmin M. Cytomegalovirus colitis in AIDS: presentation in 44 patients and a review of the literature. J Acquir Immune Defic Syndr. 1991;4 (Suppl 1):S29–S35. [PubMed] [Google Scholar]
- Hing M. C., Goldschmidt C., Mathijs J. M., Cunningham A. L., Cooper D. A. Chronic colitis associated with human immunodeficiency virus infection. Med J Aust. 1992 May 18;156(10):683–687. doi: 10.5694/j.1326-5377.1992.tb121507.x. [DOI] [PubMed] [Google Scholar]
- Katlama C., Dohin E., Caumes E., Cochereau-Massin I., Brancon C., Robinet M., Rogeaux O., Dahan R., Gentilini M. Foscarnet induction therapy for cytomegalovirus retinitis in AIDS: comparison of twice-daily and three-times-daily regimens. J Acquir Immune Defic Syndr. 1992;5 (Suppl 1):S18–S24. [PubMed] [Google Scholar]
- Kotler D. P., Reka S., Clayton F. Intestinal mucosal inflammation associated with human immunodeficiency virus infection. Dig Dis Sci. 1993 Jun;38(6):1119–1127. doi: 10.1007/BF01295730. [DOI] [PubMed] [Google Scholar]
- Nelson M. R., Connolly G. M., Hawkins D. A., Gazzard B. G. Foscarnet in the treatment of cytomegalovirus infection of the esophagus and colon in patients with the acquired immune deficiency syndrome. Am J Gastroenterol. 1991 Jul;86(7):876–881. [PubMed] [Google Scholar]
- Sjövall J., Karlsson A., Ogenstad S., Sandström E., Saarimäki M. Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus. Clin Pharmacol Ther. 1988 Jul;44(1):65–73. doi: 10.1038/clpt.1988.114. [DOI] [PubMed] [Google Scholar]
- Weber J. N., Thom S., Barrison I., Unwin R., Forster S., Jeffries D. J., Boylston A., Pinching A. J. Cytomegalovirus colitis and oesophageal ulceration in the context of AIDS: clinical manifestations and preliminary report of treatment with Foscarnet (phosphonoformate). Gut. 1987 Apr;28(4):482–487. doi: 10.1136/gut.28.4.482. [DOI] [PMC free article] [PubMed] [Google Scholar]